REGN logo

REGNRegeneron Pharmaceuticals, Inc.

$639.47
$20.52
(3.32%)
Pre-Market
Updated: 05:50 AM EDT·Prev Close $618.95
EarningsJul 30
Mkt Cap$63.21B
Vol984.00
News
all
press releases
Are Options Traders Betting on a Big Move in Regeneron Stock?
Investors need to pay close attention to REGN stock based on the movements in the options market lately.
Zacks
News Placeholder
More News
News Placeholder
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound? (Revised)
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength (Revised)
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Zacks
News Placeholder
Regeneron (REGN) Down 12.1% Since Last Earnings Report: Can It Rebound?
Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
RSI Alert: Regeneron Pharmaceuticals (REGN) Now Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
News Placeholder
Here's Why Regeneron (REGN) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN PR Newswire NEW YORK, May 21, 2026 NEW YORK, May 21, 2026...
PR Newswire
News Placeholder
BAYRY's Kerendia Label Expansion Application Gets Priority Review
Bayer wins FDA Priority Review for Kerendia label expansion in CKD tied to type I diabetes after strong phase III data.
Zacks
News Placeholder
$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
read more...
Benzinga
News Placeholder
REGN Investor Alert: Levi & Korsinsky Investigates Regeneron Pharmaceuticals, Inc. (REGN) for Potential Securities Fraud
Regeneron Pharmaceuticals (NASDAQ: REGN) shares dropped sharply after the Company disclosed on May 16, 2026, that its Phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to meet its primary endpoint versus Merck's Keytruda. Shareholders who lost money on REGN are...
Business Wire
<
1
2
...
>